Last reviewed · How we verify
Rabies mRNA vaccine CV7202
Rabies mRNA vaccine CV7202 is a Biologic drug developed by CureVac. It is currently in Phase 1 development.
At a glance
| Generic name | Rabies mRNA vaccine CV7202 |
|---|---|
| Sponsor | CureVac |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabies mRNA vaccine CV7202 CI brief — competitive landscape report
- Rabies mRNA vaccine CV7202 updates RSS · CI watch RSS
- CureVac portfolio CI
Frequently asked questions about Rabies mRNA vaccine CV7202
What is Rabies mRNA vaccine CV7202?
Rabies mRNA vaccine CV7202 is a Biologic drug developed by CureVac.
Who makes Rabies mRNA vaccine CV7202?
Rabies mRNA vaccine CV7202 is developed by CureVac (see full CureVac pipeline at /company/curevac).
What development phase is Rabies mRNA vaccine CV7202 in?
Rabies mRNA vaccine CV7202 is in Phase 1.
Related
- Manufacturer: CureVac — full pipeline
- Compare: Rabies mRNA vaccine CV7202 vs similar drugs
- Pricing: Rabies mRNA vaccine CV7202 cost, discount & access